Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1403

1.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
2.

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group..

Arch Intern Med. 2002 Sep 23;162(17):1973-80.

PMID:
12230420
3.

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A.

AIDS. 2004 Dec 3;18(18):2419-23.

PMID:
15622318
4.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
5.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
6.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
7.

The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study.

Anastos K, Kalish LA, Hessol N, Weiser B, Melnick S, Burns D, Delapenha R, DeHovitz J, Cohen M, Meyer W, Bremer J, Kovacs A.

AIDS. 1999 Sep 10;13(13):1717-26. Erratum in: AIDS 2000 May 5;14(7):891.

PMID:
10509574
8.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators..

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
9.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
10.
11.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.

Ann Intern Med. 1997 Jun 15;126(12):946-54.

PMID:
9182471
13.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
14.
15.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.

PMID:
12960823
16.

Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.

Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, DeHovitz J, Delapenha R, Hoover DR.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):383-92.

PMID:
15097155
17.
18.

Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.

AIDS. 2004 Oct 21;18(15):2029-38.

PMID:
15577624
19.

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN; EuroSIDA Study Group..

AIDS. 2005 Feb 18;19(3):319-30.

PMID:
15718843
20.

[Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].

Reus S, Portilla J, Gimeno A, Sánchez-Payá J, García-Henarejos JA, Martínez-Madrid O, Usó J, Roca B, Galindo MJ, López-Aldeguer J.

Enferm Infecc Microbiol Clin. 2004 Mar;22(3):142-9. Spanish.

PMID:
14987534
Items per page

Supplemental Content

Support Center